RxDoctor Payments Data

Imtiazuddin Siddiqui, MD

Psychiatry · Pompton Plains, NJNPI 1851477186

Payments from drug & device makers

$1,967in general payments, 2019–2025

Across 146 payments — averaging $13.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$319
  • E.r. Squibb & Sons, L.L.C.$306
  • Neurocrine Biosciences, Inc.$199
  • Teva Pharmaceuticals USA, Inc.$192
  • Vanda Pharmaceuticals Inc.$172
  • Otsuka America Pharmaceutical, Inc.$171
  • plus $607 from 7 others

What the payments were for

  • Food & beverage$1,94299%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,967 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$148,909
Medicare patients
373
Services billed
1,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$169,064
Invega SustennaPaliperidone Palmitate47$121,256
VraylarCariprazine Hcl33$48,492
Abilify MaintenaAripiprazole18$38,882
ValiumDiazepam13$25,104
Risperidone ErRisperidone Microspheres13$23,594
TrintellixVortioxetine Hydrobromide41$22,550
FanaptIloperidone12$17,661
Aripiprazole170$16,887
ZoloftSertraline Hcl15$16,765
ClozarilClozapine11$16,244
Lurasidone Hcl39$14,833
Clozapine152$14,371
Oxcarbazepine179$9,682
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$7,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$199$169,06420 claims
Johnson & JohnsonInvega Sustenna$102$121,25647 claims
AbbVieVraylar$122$48,49233 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$171$38,88218 claims
Vanda Pharmaceuticals Inc.Fanapt$172$17,66112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Pompton Plains

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →